NUVB
Nuvation Bio Inc.
$4.80
-0.41%
$1.7B
No data for this timeframe.
Vol
Market Cap$1.7B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (88%)
Inst. Holders7 funds
Inst. Value$672.8M
Inst. Activity2 buys / 1 sells
Insider Activity0B / 3S
Insider Net $-$1.3M
Reddit Sentiment63° Warm
SEC Reports3
Recent Activity
Jun 9, 2026
short_volume
Short Volume: NUVB — 71.0% short (3.3M / 4.6M)
Short: 3,289,166 | Exempt: 5,937 | TRF Vol: 4,631,359 | Short Ratio: 71.0% | Off-exchange volume (da
May 21, 2026
Insider
FALBERG KATHRYN E sold 123,397 shares
Director @ $0.00 ($0.00)
May 21, 2026
Insider
Mashal Robert sold 123,397 shares
Director @ $0.00 ($0.00)
May 21, 2026
Insider
Cui Xiangmin sold 123,397 shares
Director @ $0.00 ($0.00)
May 4, 2026
SEC
Nuvation Bio reported Q1 2026 total revenue of $83.2M (up from $3.1M YoY) and net income of $5.4M ($0.01 diluted EPS) vs
8-K — Impact 6/10
Apr 21, 2026
SEC
Nuvation Bio Inc. filed a supplemental proxy statement to correct a typographical error in the non-employee director com
DEFA14A — Impact 2/10
Apr 17, 2026
SEC
Kerry Wentworth, an officer of Nuvation Bio Inc., filed a Form 144 to sell up to 36,750 shares of common stock, valued a
144 — Impact 3/10
Inst.
BANK OF AMERICA CORP — DOUBLED
3,809,425 shares ($34.1M)
Price Targets
$12.33
+150.2% upside
Strong Buy
Current $4.93
Low $7.00
Median $12.00
High $20.00
9 analysts
$7.00
$20.00
Analyst Ratings
4Strong Buy
11Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 5, 2026 | RBC Capital | REITERATE | Outperform → Outperform |
| May 5, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 16, 2026 | Wedbush | REITERATE | Outperform → Outperform |
| Apr 2, 2026 | Wedbush | REITERATE | Outperform → Outperform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.12 ▼ -9.1% | $-0.12 — $-0.12 | 13% YoY | 1 |
| Next Q | $-0.11 ▼ -22.2% | $-0.11 — $-0.11 | 21% YoY | 1 |
| Current FY | $-0.28 ▼ -27.3% | $-0.28 — $-0.28 | 43% YoY | 1 |
| Next FY | $-0.06 ▲ +58.6% | $-0.06 — $-0.06 | 79% YoY | 1 |
Latest Reports
MIXED
8-K
6/10
Nuvation Bio reported Q1 2026 total revenue of $83.2M (up from $3.1M YoY) and net income of $5.4M ($0.01 diluted EPS) vs
May 4, 2026
NEUTRAL
DEFA14A
2/10
Nuvation Bio Inc. filed a supplemental proxy statement to correct a typographical error in the non-employee director com
Apr 21, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| FMR LLC | $460.8M | — |
| VANGUARD GROUP INC | $139.4M | — |
| BANK OF AMERICA CORP | $34.1M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $18.1M | ADD |
| MORGAN STANLEY | $11.4M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 21, 2026 | FALBERG KATHRYN | A | $0.00 |
| May 21, 2026 | Mashal Robert | A | $0.00 |
| May 21, 2026 | Cui Xiangmin | A | $0.00 |
| May 21, 2026 | Bazemore Robert | A | $0.00 |
| May 21, 2026 | BLICKENSTAFF KIM | A | $0.00 |
Reddit Sentiment
63°
Warm
Bearish
Neutral
Bullish
7 institutional holders with $672.8M total value (75,090,703 shares) as of 2025-Q4. Top holders: FMR, VANGUARD, BANK. Net buying activity: 2 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | FMR LLC | 51,424,981 | $460.8M | 68.5% | — |
| 2 | VANGUARD GROUP INC | 15,555,606 | $139.4M | 20.7% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 3,809,425 | $34.1M | 5.1% | DOUBLED +505.5% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,016,681 | $18.1M | 2.7% | ADD +39.6% |
| 5 | MORGAN STANLEY | 1,276,128 | $11.4M | 1.7% | TRIM -38.6% |
| 6 | TWO SIGMA INVESTMENTS, LP | 735,945 | $6.6M | 1.0% | TRIM -69.0% |
| 7 | WELLS FARGO & COMPANY/MN | 271,937 | $2.4M | 0.4% | ADD +43.6% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 629,162 | 3,809,425 | +505.5% | $34.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 2,377,570 | 735,945 | -69.0% | $6.6M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 189,342 | 271,937 | +43.6% | $2.4M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 1,214,733 | 2,377,570 | +95.7% | $8.8M | 2025-Q3 |
| UBS Group AG | ADD | 473,939 | 908,101 | +91.6% | $3.4M | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 209,641 | 629,162 | +200.1% | $2.3M | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 22,100 | 0 | -100.0% | $0.00 | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 687,378 | 1,214,733 | +76.7% | $2.4M | 2025-Q2 |
| MORGAN STANLEY | TRIM | 1,969,970 | 1,209,803 | -38.6% | $2.4M | 2025-Q2 |
| UBS Group AG | TRIM | 871,692 | 473,939 | -45.6% | $924.2K | 2025-Q2 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 103,363 | 209,641 | +102.8% | $408.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | ADD | 108,822 | 158,683 | +45.8% | $309.4K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 444,100 | 22,100 | -95.0% | $43.1K | 2025-Q2 |
| MORGAN STANLEY | ADD | 1,072,836 | 1,969,970 | +83.6% | $3.5M | 2025-Q1 |
| UBS Group AG | TRIM | 1,850,693 | 871,692 | -52.9% | $1.5M | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | TRIM | 1,151,256 | 687,378 | -40.3% | $1.2M | 2025-Q1 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | ADD | 1,394,015 | 1,945,983 | +39.6% | $5.2M | 2024-Q4 |
| UBS Group AG | DOUBLED | 465,109 | 1,850,693 | +297.9% | $4.9M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,029,000 | 566,800 | -44.9% | $1.5M | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 83,238 | 106,416 | +27.8% | $283.1K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 1,394,015 | — | $3.2M | 2024-Q3 |
15 unique insiders with 3 transactions. Net insider value: -$1.3M ($0.00 bought, $1.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 21, 2026 | FALBERG KATHRYN E | Director | A | 123,397 | $0.00 | $0.00 |
| May 21, 2026 | Mashal Robert | Director | A | 123,397 | $0.00 | $0.00 |
| May 21, 2026 | Cui Xiangmin | Director | A | 123,397 | $0.00 | $0.00 |
| May 21, 2026 | Bazemore Robert B | Director | A | 123,397 | $0.00 | $0.00 |
| May 21, 2026 | BLICKENSTAFF KIM D | Director | A | 123,397 | $0.00 | $0.00 |
| May 21, 2026 | VERNON W ANTHONY | Director | A | 123,397 | $0.00 | $0.00 |
| Apr 17, 2026 | Liu Dongfang | CHIEF MEDICAL OFFICER | M | 50,000 | $1.94 | $97.0K |
| Apr 17, 2026 | Liu Dongfang | CHIEF MEDICAL OFFICER | SELL | 50,000 | $5.02 | $251.0K |
| Apr 17, 2026 | Liu Dongfang | CHIEF MEDICAL OFFICER | M | 50,000 | $0.00 | $0.00 |
| Apr 17, 2026 | Wentworth Kerry | CHIEF REGULATORY OFFICER | M | 36,750 | $2.93 | $107.7K |
| Apr 17, 2026 | Wentworth Kerry | CHIEF REGULATORY OFFICER | SELL | 36,750 | $5.01 | $184.3K |
| Apr 17, 2026 | Wentworth Kerry | CHIEF REGULATORY OFFICER | M | 36,750 | $0.00 | $0.00 |
| Apr 6, 2026 | Wentworth Kerry | CHIEF REGULATORY OFFICER | M | 100,000 | $0.00 | $0.00 |
| Apr 6, 2026 | Wentworth Kerry | CHIEF REGULATORY OFFICER | M | 100,000 | $1.87 | $187.0K |
| Apr 6, 2026 | Wentworth Kerry | CHIEF REGULATORY OFFICER | SELL | 200,000 | $4.52 | $903.6K |
| Feb 27, 2026 | Cui Xiangmin | Director | A | 76,923 | $0.00 | $0.00 |
| Feb 27, 2026 | Makunje Moses | SEE REMARKS | A | 50,761 | $0.00 | $0.00 |
| Feb 27, 2026 | Makunje Moses | SEE REMARKS | A | 224,439 | $0.00 | $0.00 |
| Feb 27, 2026 | Liu Dongfang | CHIEF MEDICAL OFFICER | A | 748,130 | $0.00 | $0.00 |
| Feb 27, 2026 | Wentworth Kerry | CHIEF REGULATORY OFFICER | A | 748,130 | $0.00 | $0.00 |
| Feb 27, 2026 | Sjogren Colleen | Chief Commercial Officer | A | 748,130 | $0.00 | $0.00 |
| Feb 27, 2026 | Sauvage Philippe | Chief Financial Officer | A | 748,130 | $0.00 | $0.00 |
| Feb 27, 2026 | Markel Stacy | CHIEF PEOPLE OFFICER | A | 748,130 | $0.00 | $0.00 |
| Feb 27, 2026 | Cui Xiangmin | Director | A | 74,813 | $0.00 | $0.00 |
| Feb 27, 2026 | Hattersley Gary | CHIEF SCIENTIFIC OFFICER | A | 748,130 | $0.00 | $0.00 |
| Feb 27, 2026 | Hanley David C. | CHIEF TECHNICAL OPERATIONS | A | 748,130 | $0.00 | $0.00 |
| Feb 27, 2026 | Hung David | PRESIDENT AND CEO | A | 1,995,012 | $0.00 | $0.00 |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 3.7/10.
MIXED
8-K
6/10
Nuvation Bio reported Q1 2026 total revenue of $83.2M (up from $3.1M YoY) and net income of $5.4M ($
May 4, 2026
NEUTRAL
DEFA14A
2/10
Nuvation Bio Inc. filed a supplemental proxy statement to correct a typographical error in the non-e
Apr 21, 2026
NEUTRAL
144
3/10
Kerry Wentworth, an officer of Nuvation Bio Inc., filed a Form 144 to sell up to 36,750 shares of co
Apr 17, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Strong Buy (88% buy). Based on 17 analysts: 4 strong buy, 11 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$12.33 mean target
+150.2% upside
Strong Buy (1.40)
$7.00 Low
$20.00 High
| Metric | Value |
|---|---|
| Current Price | $4.93 |
| Target Low | $7.00 |
| Target Mean | $12.33 |
| Target Median | $12.00 |
| Target High | $20.00 |
| # Analysts | 9 |
| Recommendation | Strong Buy (1.40) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.12 | $-0.12 | $-0.12 | 13.0% | -9.1% | 0↑ 1↓ | $0.0B | 474.0% | 1 |
| Next Q 2026-09-30 |
$-0.11 | $-0.11 | $-0.11 | 21.1% | -22.2% | 0↑ 1↓ | $0.0B | 201.1% | 1 |
| Current FY 2026-12-31 |
$-0.28 | $-0.28 | $-0.28 | 43.3% | -27.3% | 0↑ 1↓ | $0.2B | 222.1% | 1 |
| Next FY 2027-12-31 |
$-0.06 | $-0.06 | $-0.06 | 78.6% | +58.6% | 0↑ 1↓ | $0.3B | 43.3% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.120 | |
| 7d ago | $-0.110 | -0.010 |
| 30d ago | $-0.110 | -0.010 |
| 60d ago | $-0.100 | -0.020 |
| 90d ago | $0.000 | -0.120 |
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 5, 2026 | RBC Capital | REITERATE | Outperform | Outperform |
| May 5, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| May 5, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 16, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Apr 2, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 27, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Mar 3, 2026 | UBS | MAINTAIN | Neutral | Neutral |
| Mar 3, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Feb 10, 2026 | Wedbush | REITERATE | Outperform | Outperform |
| Jan 21, 2026 | RBC Capital | MAINTAIN | Outperform | Outperform |
| Jan 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 7, 2026 | UBS | INITIATE | — | Neutral |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 11 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 4 | 11 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 4 | 11 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 4 | 11 | 2 | 0 | 0 | 88% | |
| Feb 1, 2026 | 4 | 11 | 2 | 0 | 0 | 88% | |
| Jan 1, 2026 | 4 | 11 | 1 | 0 | 0 | 94% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
63°
Warm
Bearish
Neutral
Bullish
4 mentions
2 bullish
0 bearish
4 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 4, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Jun 4, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| May 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 5, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Why NUVB is a gem - in the low 5's.
▲ 1
💬 0
⚡ 0.5
Gambling my 401k/Roth from 10k -> $2M ($DOCN & others)
▲ 1
💬 1
⚡ 0.5
Jun 9, 2026
short_volume
Short Volume: NUVB — 71.0% short (3.3M / 4.6M)
Short: 3,289,166 | Exempt: 5,937 | TRF Vol: 4,631,359 | Short Ratio: 71.0% | Off-exchange volume (dark pool + OTC)
Jun 8, 2026
short_volume
Short Volume: NUVB — 62.1% short (0.7M / 1.2M)
Short: 749,880 | Exempt: 1,500 | TRF Vol: 1,206,807 | Short Ratio: 62.1% | Off-exchange volume (dark pool + OTC)
Jun 5, 2026
short_volume
Short Volume: NUVB — 61.6% short (0.8M / 1.2M)
Short: 753,602 | Exempt: 5,956 | TRF Vol: 1,223,208 | Short Ratio: 61.6% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: NUVB — 56.4% short (0.7M / 1.2M)
Short: 650,545 | Exempt: 162 | TRF Vol: 1,154,377 | Short Ratio: 56.4% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: NUVB — 63.8% short (1.0M / 1.6M)
Short: 1,040,108 | Exempt: 1,776 | TRF Vol: 1,630,479 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: NUVB — 72.3% short (1.7M / 2.3M)
Short: 1,663,619 | Exempt: 4,228 | TRF Vol: 2,300,226 | Short Ratio: 72.3% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: NUVB — 64.9% short (0.9M / 1.4M)
Short: 910,715 | Exempt: 8,038 | TRF Vol: 1,402,260 | Short Ratio: 64.9% | Off-exchange volume (dark pool + OTC)
May 28, 2026
short_volume
Short Volume: NUVB — 63.8% short (0.4M / 0.6M)
Short: 413,089 | Exempt: 100 | TRF Vol: 647,164 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: NUVB — 58.7% short (0.7M / 1.2M)
Short: 730,223 | Exempt: 59,627 | TRF Vol: 1,244,417 | Short Ratio: 58.7% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: NUVB — 78.2% short (2.0M / 2.5M)
Short: 1,952,776 | Exempt: 10,217 | TRF Vol: 2,497,362 | Short Ratio: 78.2% | Off-exchange volume (dark pool + OTC)
May 20, 2026
short_volume
Short Volume: NUVB — 65.9% short (1.5M / 2.3M)
Short: 1,496,879 | Exempt: 750 | TRF Vol: 2,271,543 | Short Ratio: 65.9% | Off-exchange volume (dark pool + OTC)
May 19, 2026
short_volume
Short Volume: NUVB — 61.2% short (1.2M / 1.9M)
Short: 1,187,364 | Exempt: 517 | TRF Vol: 1,939,354 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: NUVB — 68.2% short (1.5M / 2.3M)
Short: 1,549,148 | Exempt: 62 | TRF Vol: 2,272,036 | Short Ratio: 68.2% | Off-exchange volume (dark pool + OTC)
May 15, 2026
short_volume
Short Volume: NUVB — 78.2% short (3.2M / 4.0M)
Short: 3,158,496 | Exempt: 38,665 | TRF Vol: 4,036,593 | Short Ratio: 78.2% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: NUVB — 58.8% short (1.2M / 2.0M)
Short: 1,152,079 | Exempt: 39,814 | TRF Vol: 1,958,811 | Short Ratio: 58.8% | Off-exchange volume (dark pool + OTC)